NL8101724A - Peptiden met zenuw-regenererende eigenschappen. - Google Patents
Peptiden met zenuw-regenererende eigenschappen. Download PDFInfo
- Publication number
- NL8101724A NL8101724A NL8101724A NL8101724A NL8101724A NL 8101724 A NL8101724 A NL 8101724A NL 8101724 A NL8101724 A NL 8101724A NL 8101724 A NL8101724 A NL 8101724A NL 8101724 A NL8101724 A NL 8101724A
- Authority
- NL
- Netherlands
- Prior art keywords
- met
- peptides
- peptide
- phe
- nerve
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 31
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 22
- 210000005036 nerve Anatomy 0.000 title description 8
- 230000001172 regenerating effect Effects 0.000 title description 2
- 239000012634 fragment Substances 0.000 claims description 6
- 230000008929 regeneration Effects 0.000 claims description 6
- 238000011069 regeneration method Methods 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 230000003376 axonal effect Effects 0.000 claims description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims description 3
- 102000007079 Peptide Fragments Human genes 0.000 claims description 3
- 108010033276 Peptide Fragments Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical group C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 3
- 229960000258 corticotropin Drugs 0.000 claims description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 2
- HKTRDWYCAUTRRL-YUMQZZPRSA-N Glu-His Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 HKTRDWYCAUTRRL-YUMQZZPRSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 108010056243 alanylalanine Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 239000012059 conventional drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 9
- 230000006378 damage Effects 0.000 description 7
- 210000000653 nervous system Anatomy 0.000 description 5
- 208000028389 Nerve injury Diseases 0.000 description 4
- 230000008764 nerve damage Effects 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036362 sensorimotor function Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-Glutamic acid Natural products OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010073696 Wallerian degeneration Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002972 tibial nerve Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008734 wallerian degeneration Effects 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/695—Corticotropin [ACTH]
- C07K14/6955—Corticotropin [ACTH] with at least 1 amino acid in D-form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/695—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8101724A NL8101724A (nl) | 1981-04-08 | 1981-04-08 | Peptiden met zenuw-regenererende eigenschappen. |
| EP82901123A EP0076818A1 (de) | 1981-04-08 | 1982-04-05 | Peptide mit eigenschaften zur regenerierung der nerven |
| DE3239710T DE3239710C2 (de) | 1981-04-08 | 1982-04-05 | Peptid mit Nerven-regenerierenden Eigenschaften |
| JP57501186A JPS58500481A (ja) | 1981-04-08 | 1982-04-05 | 神経再生特性を有するペプチド |
| PCT/EP1982/000079 WO1982003388A1 (en) | 1981-04-08 | 1982-04-05 | Peptides with nerve-regenerating properties |
| IT67461/82A IT1155507B (it) | 1981-04-08 | 1982-04-07 | Peptidi rigeneratori dei nervi |
| US06/658,544 US4550099A (en) | 1981-04-08 | 1984-10-09 | Peptides with nerve-regenerating properties |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8101724A NL8101724A (nl) | 1981-04-08 | 1981-04-08 | Peptiden met zenuw-regenererende eigenschappen. |
| NL8101724 | 1981-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8101724A true NL8101724A (nl) | 1982-11-01 |
Family
ID=19837321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8101724A NL8101724A (nl) | 1981-04-08 | 1981-04-08 | Peptiden met zenuw-regenererende eigenschappen. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4550099A (de) |
| EP (1) | EP0076818A1 (de) |
| JP (1) | JPS58500481A (de) |
| DE (1) | DE3239710C2 (de) |
| IT (1) | IT1155507B (de) |
| NL (1) | NL8101724A (de) |
| WO (1) | WO1982003388A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE56254B1 (en) * | 1982-11-10 | 1991-06-05 | Akzo Nv | Peptides |
| EP0146113A3 (de) * | 1983-12-15 | 1987-08-19 | Dieter Aderhold | Wirkstoff und therapeutisches Mittel zur Behandlung von Fehlfunktionen des Diencephalon, von Nervenerkrankungen und Erkrankungen der Haut |
| DE3345358A1 (de) * | 1983-12-15 | 1985-06-27 | Dieter Prof. Dr. Dr. 5883 Kierspe Aderhold | Therapeutisches mittel zur behandlung von fehlfunktionen des menschlichen diencephalon und/oder der hypophyse, insbesondere der multiplen sklerose |
| IE911802A1 (en) * | 1990-06-13 | 1991-12-18 | Akzo Nv | Crystalline polypeptides |
| IE912091A1 (en) * | 1990-07-18 | 1992-01-29 | Akzo Nv | Use of a centrally acting atch analog in the manufacture of a¹medicament |
| US5189018A (en) * | 1991-08-19 | 1993-02-23 | Wayne State University | Method for reduction of central nervous system (cns) edema resulting from head and spinal cord trauma |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL175174C (nl) * | 1972-03-31 | 1984-10-01 | Akzo Nv | Werkwijze ter bereiding van een farmaceutisch preparaat met psychofarmacologische werking, dat een peptide of peptide-derivaat als actief bestanddeel bevat, alsmede een werkwijze ter bereiding van deze peptiden. |
| NL175988C (nl) * | 1972-05-24 | 1985-02-01 | Akzo Nv | Werkwijze ter bereiding van een farmaceutisch preparaat met psychofarmacologische werking, dat een peptide of peptide-derivaat dat afgeleid is van een de aminozuren 4-10 omvattend, fragment van adrenocorticotroop hormoon als actief bestanddeel bevat, alsmede een werkwijze ter bereiding van deze peptiden. |
| NL7607683A (nl) * | 1976-07-12 | 1978-01-16 | Akzo Nv | Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan. |
| FR2328453A1 (fr) * | 1975-10-21 | 1977-05-20 | Drouhault Robert | Peptide marque au 99mtc |
| NL7607684A (nl) * | 1976-07-12 | 1978-01-16 | Akzo Nv | Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan. |
-
1981
- 1981-04-08 NL NL8101724A patent/NL8101724A/nl not_active Application Discontinuation
-
1982
- 1982-04-05 EP EP82901123A patent/EP0076818A1/de not_active Withdrawn
- 1982-04-05 JP JP57501186A patent/JPS58500481A/ja active Granted
- 1982-04-05 WO PCT/EP1982/000079 patent/WO1982003388A1/en active Application Filing
- 1982-04-05 DE DE3239710T patent/DE3239710C2/de not_active Expired - Fee Related
- 1982-04-07 IT IT67461/82A patent/IT1155507B/it active
-
1984
- 1984-10-09 US US06/658,544 patent/US4550099A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US4550099A (en) | 1985-10-29 |
| JPS58500481A (ja) | 1983-03-31 |
| JPH0361653B2 (de) | 1991-09-20 |
| IT8267461A0 (it) | 1982-04-07 |
| EP0076818A1 (de) | 1983-04-20 |
| IT1155507B (it) | 1987-01-28 |
| DE3239710T1 (de) | 1983-06-16 |
| WO1982003388A1 (en) | 1982-10-14 |
| DE3239710C2 (de) | 1994-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69636343T2 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| DE2217817C2 (de) | Pharmazeutisches Präparat zur Behandlung von oder zum Schutz gegen autoimmune Erkrankungen, die das Gehirn angreifen | |
| KR100298763B1 (ko) | 말초신경병의예방및치료 | |
| EP0067425B1 (de) | Gegebenenfalls geschützte Peptide, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| KR20200143407A (ko) | Cgrp를 억제하는데 사용하기 위한 신경독소 | |
| RU2155063C1 (ru) | Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения | |
| EP0034259A1 (de) | Peptidester, Verfahren zur Herstellung derselben und diese enthaltende Arzneimittel beziehungsweise Diagnostica | |
| JP2000508629A (ja) | 筋痙攣およびそれに関連する疼痛を除去するための注射療法 | |
| EP0346501B1 (de) | Arzneimittelzubereitung zur behandlung des immunmangels | |
| RU2341284C2 (ru) | Применение эритропоэтина в восстановлении после инсульта | |
| JP2000512613A (ja) | ペプチド複合体、医薬品としてのその用途およびそれを含有する組成物 | |
| EP1183047A2 (de) | Proteinenthaltende pharmazeutische zubereitung | |
| NL8101724A (nl) | Peptiden met zenuw-regenererende eigenschappen. | |
| DE4203040A1 (de) | Neue parathormonfragmente, deren herstellung und diese enthaltende arzneimittel | |
| DE69633396T2 (de) | Activin stimulator enthaltende pharmazeutische zusammensetzung | |
| CH676425A5 (de) | ||
| DE60205366T2 (de) | Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine | |
| JP6912834B2 (ja) | ボツリヌス毒素及びヒアルロン酸を含む足部痛疾患の治療用薬学的組成物及びこれを利用した足部痛疾患の治療方法 | |
| DE3117948A1 (de) | Anorexigene peptide | |
| DE69826653T2 (de) | Bpc peptid salze mit organ-schützender aktivität, deren herstellung und therapeutische verwendung | |
| LT96079A (en) | Use of corticotropin-releasing factor for the manufacture of a medicaments | |
| DE69233315T2 (de) | Pharmazeutische lysin enthaltende polypeptid-zusammensetzungen und verfahren zu deren verwendung | |
| NZ541493A (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| CN111569046B (zh) | 多肽在制备治疗胰腺炎药物中的用途及含有其的药物 | |
| DE60110247T2 (de) | Angiogenische Tri- oder Tetrapeptide abgeleitet von AcSDKP |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |